🔎 Trials Near Me

Home › Cannabis › NCT07603518

The Pharmacokinetics of a Hemp-Based Topical Product

RecruitingPhase 1Healthy volunteers welcome

The Pharmacokinetics of a Hemp-Based Topical Cannabinoid Product in a Sanitized and Controlled Environment

Who can join

Ages 18 to 55 · All sexes · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria:

* Have provided written informed consent
* Be between the ages of 18 and 55
* Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
* Test negative for recent cannabis use in urine at the screening visit and again upon admission for the inpatient stay.
* Test negative for other drugs of abuse, including alcohol, at the screening visit and again upon admission for the inpatient stay.
* Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at each study visit.
* Have a body mass index (BMI) in the range of 18 to 38 kg/m2
* Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg
* Report prior experience using cannabis or CBD products.

Exclusion Criteria:

* Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine in the month prior to the screening visit.
* History of or current evidence of significant medical or psychiatric illness judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.
* Current use of medications which, in the opinion of the investigator or medical monitor, will interfere with the study results or the safety of the subject.
* History of xerostomia (dry mouth), or the presence of mucositis, gum infection or bleeding, or other significant oral cavity disease or disorder that in the investigator's opinion may affect the collection of oral fluid samples.
* Known allergy to any ingredients in the study drug.
* Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing.

About the study

This study will evaluate the pharmacokinetic effects of acute and chronic dosing of a hemp-based cannabidiol (CBD) topical lotion with low levels of delta-9-tetrahydrocannabinol (THC) in a sanitized and controlled environment.

What is being tested

Sponsor: Johns Hopkins University · Participants: 20 · Started: May 26, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07603518

Locations in the U.S.

MarylandBehavioral Pharmacology Research Unit, Baltimore

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.